

9-2015

Response of mammalian macrophages to challenge with the Chlorovirus ATCV-1

Thomas M. Petro

University of Nebraska-Lincoln, tpetro@unmc.edu

Irina V. Agarkova

University of Nebraska-Lincoln, iagarkova2@unl.edu

You Zhou

University of Nebraska-Lincoln, yzhou2@unl.edu

Robert H. Yolken

Johns Hopkins University School of Medicine, yolken@mail.jhmi.edu

James L. Van Etten

University of Nebraska-Lincoln, jvanetten1@unl.edu

See next page for additional authors

Follow this and additional works at: <http://digitalcommons.unl.edu/virologypub>

 Part of the [Biology Commons](#), [Cell and Developmental Biology Commons](#), and the [Ecology and Evolutionary Biology Commons](#)

Petro, Thomas M.; Agarkova, Irina V.; Zhou, You; Yolken, Robert H.; Van Etten, James L.; and Dunigan, David D., "Response of mammalian macrophages to challenge with the Chlorovirus ATCV-1" (2015). *Virology Papers*. 279.
<http://digitalcommons.unl.edu/virologypub/279>

This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Thomas M. Petro, Irina V. Agarkova, You Zhou, Robert H. Yolken, James L. Van Etten, and David D. Dunigan

1 **Response of mammalian macrophages to** 2 **challenge with the *Chlorovirus* ATCV-1**

3 **Thomas M. Petro^{1,2#}, Irina V. Agarkova^{1,3}, You Zhou^{1,5}, Robert H. Yolken⁴, James L.**
4 **Van Etten^{1,3}, David D. Dunigan^{1,3#}**

5 (1)Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68583-
6 0900; (2)Department of Oral Biology, University of Nebraska-Medical Center, Lincoln,
7 NE 68583; (3)Department of Plant Pathology, University of Nebraska-Lincoln, Lincoln,
8 NE 68583; (4)Stanley Division of Developmental Neurovirology, Johns Hopkins
9 University School of Medicine, Baltimore, MD 21287; (5) Center for Biotechnology,
10 University of Nebraska-Lincoln

11

12 **Running Head:** Chlorovirus ATCV-1 and macrophage responses

13

14 **#Address correspondence to:** Thomas M. Petro, tpetro@unmc.edu

15 David D. Dunigan, ddunigan2@unl.edu

16

17 **Word Count:** 5,226
18 250 Words in Abstract

19

20 **ABSTRACT**

21 It was recently reported that 44% of healthy humans in a study cohort had DNA
22 sequences similar to *Chlorovirus* ATCV-1 (family *Phycodnaviridae*) in oropharyngeal
23 samples and had decreases in visual processing and visual motor speed compared with
24 individuals in whom no virus was detected. Moreover, mice inoculated orally with
25 ATCV-1 developed immune responses to ATCV-1 proteins and had decreases in
26 certain cognitive domains. Because heightened IL-6, nitric oxide (NO), and ERK MAP-
27 kinase activation from macrophages are linked to cognitive impairments, we evaluated
28 cellular responses and viral plaque forming units in murine RAW264.7 and primary
29 macrophages after exposure to ATCV-1 *in vitro* for up to 72 h after virus challenge.
30 Approximately 8% of the ATCV-1 inoculum was associated with macrophages after 1 h
31 and increased 2-3 fold over 72 h. Immunoblots using rabbit anti-ATCV-1 detected a 55
32 kDa protein consistent with viral capsid protein from 1 to 72 h and an increasing *de*
33 *novo* synthesis of a previously unidentified 17 kDa protein beginning at 24 h.
34 Emergence of the 17 kDa protein did not occur and persistence of the 55 kDa protein
35 declined over time when cells were exposed to heat-inactivated ATCV-1. Moreover,
36 starting at 24 h, RAW264.7 cells exhibited cytopathic effects, Annexin V staining and
37 cleaved-caspase 3. Activation of ERK MAP-kinases occurred in these cells by 30 min
38 post challenge, which preceded expression of IL-6 and NO. Therefore ATCV-1
39 persistence in and induction of inflammatory factors by these macrophages may
40 contribute to declines in cognitive abilities of mice and humans.

41

42

43 **Importance**

44 Virus infections that persist in and stimulate inflammatory factors from macrophages
45 contribute to pathologies in humans. A previous study showed that DNA sequences
46 homologous to *Chlorovirus* ATCV-1 were found in a significant fraction of oropharyngeal
47 samples from a healthy human cohort. We show here unexpectedly that ATCV-1,
48 whose only known host is an eukaryotic green alga (*Chlorella heliozoae*) that is an
49 endosymbiont of the heliozoon *Acanthocystis turfacea*, can persist within murine
50 macrophages and trigger inflammatory responses, including factors that contribute to
51 immunopathologies. The inflammatory factors that are produced in response to ATCV-1
52 include IL-6 and nitric oxide whose inductions are preceded by activation of ERK MAP-
53 kinases. Other responses of ATCV-1-challenged macrophages include an apoptotic
54 cytopathic effect, an innate anti-viral response, and a metabolic shift towards aerobic
55 glycolysis. Therefore, mammalian encounters with chloroviruses may contribute to
56 chronic inflammatory responses from macrophages.

57

58 Introduction

59 Chloroviruses (family *Phycodnaviridae*) were discovered over 35 years ago and are
60 distinctive because they are large icosahedral dsDNA viruses that infect certain
61 unicellular eukaryotic green algae, which are themselves endosymbionts within protists
62 (1). Chloroviruses are classified based upon the algal species they infect. NC64A
63 viruses infect *Chlorella variabilis* NC64A from *Paramecium bursaria*, Pbi viruses infect
64 *Micractinium conductrix* Pbi from *Paramecium bursaria*, Hydra viruses infect *Chlorella*
65 species from *Hydra viridis*, and SAG viruses infect *Chlorella heliozoae* SAG 3.83 from
66 the heliozoon *Acanthocystis turfacea*. Chloroviruses have large linear 290 to 370 kbp
67 dsDNA genomes that encode as many as 400 proteins. *Chlorovirus* ATCV-1 is the type
68 SAG 3.83 virus (2, 3). Considerable information is available on the interaction of the
69 chloroviruses with algae; however, nothing is known about their possible interaction with
70 mammalian cells. This possible interaction is relevant because a recent report indicated
71 that ATCV-1-like DNA sequences were present in 44% of oropharyngeal samples from
72 a healthy human cohort (4). Moreover, the presence of ATCV-1 DNA in this cohort was
73 correlated with decreased performance on certain cognitive tests. Experimental mice
74 exposed by gavage to ATCV-1-infected *C. heliozoae* also exhibited significant cognitive
75 impairments, specifically in recognition memory and sensory-motor gating, which was
76 associated with significant changes in expression of 1,285 genes in the hippocampus,
77 many of which are associated with immune and inflammatory responses. Therefore,
78 inflammatory responses to ATCV-1 may be associated with decreases in hippocampus
79 activity that is needed for spatial recognition memory (5).

80 Several inflammatory events and mediators are known to affect the health of the
81 central nervous system. During certain viral infections inflammatory macrophages are
82 involved in hippocampal damage (6, 7, 8, 9). Interleukin-6 (IL-6) produced from many
83 cell types including inflammatory macrophages is correlated with decreased
84 hippocampus volume during depression (10), decreased learning (11, 12), impaired
85 spatial learning and affects at the hippocampus (13). Nitric oxide (NO) produced by
86 macrophages during inflammation is also associated with memory impairments (14).
87 Therefore, ATCV-1 induction of inflammatory macrophages and mediators may be
88 related to certain memory impairments.

89 However, it is unknown if macrophages can become infected and/or respond to
90 challenges with ATCV-1, or if ATCV-1 can replicate in macrophages. Our working
91 hypothesis is that mouse macrophages interact with, take up, and respond to ATCV-1 in
92 a manner consistent with their potential role in cognitive impairments. Therefore, we
93 challenged the mouse macrophage cell line RAW264.7 and primary inflammatory
94 macrophages from C57Bl/6 mice with ATCV-1 and monitored infectivity and anti-viral
95 responses of macrophages. For comparison we challenged the BHK-21 fibroblast cell
96 line with ATCV-1 and we challenged RAW264.7 cells with chloroviruses PBCV-1 and
97 CVM-1, which are NC64A and Pbi viruses, respectively.

98

99 **MATERIALS AND METHODS**

100 **Cells, viruses, and reagents**

101 Female C57Bl/6 mice were obtained from Harlan Sprague Dawley (Bar Harbor, Maine).
102 RAW264.7 cells and BHK-21 cells were originally obtained from the American Type

103 Culture Collection (Rockville, MD) and grown in DMEM cell culture medium (Invitrogen,
104 Carlsbad, CA) containing 10% fetal bovine serum (FBS) (Invitrogen), and 50 µg/ml
105 gentamycin (Invitrogen). Inflammatory macrophages from C57Bl/6 mice were elicited
106 by i.p. injection of 2 ml sterile thioglycollate broth into mice (15). Three days later, the
107 peritoneal cavities were flushed with 2 ml DMEM and cells were incubated at 10^6 cells/2
108 ml of DMEM. After 24 h, non-adherent cells were removed and 1 ml of DMEM added.
109 Adherent peritoneal exudate cells (PECs) were greater than 90% Mac-1⁺ as determined
110 by FACS analysis and were thus inflammatory macrophages (16).

111 Virus ATCV-1 was grown in *C. heliozoae* SAG 3.83 cells, purified by successive
112 rounds of gradient centrifugation, 1% Triton-X 100 and proteinase K treatments as
113 previously described (17) with some modifications: due to the sensitivity of ATCV-1
114 virus to sucrose, two iodixanol gradient centrifugations were substituted for the sucrose
115 gradients. For additional purification of ATCV-1 to remove any extraneous co-purifying
116 proteins, an extra proteinase K with 1% Triton-X 100 treatment was added followed by a
117 third iodixanol gradient centrifugation. Consequently, the ultra-purification procedure
118 resulted in two proteinase treatments and three iodixanol gradient centrifugations.
119 PBCV-1 and CVM-1 chlorella virus were grown in *Chlorella variabilis* strain NC64A and
120 *Micractinium conductrix* Pbi, respectively, and purified as described previously (17).
121 Stock preparations were maintained in virus stabilization buffer (VSB: 10 mM Tris-HCl,
122 50 mM MgCl₂, pH 7.8) at 1×10^{11} plaque-forming units (PFU)/ml, then exchanged with
123 phosphate buffered saline (PBS) at 1×10^{10} PFU/ml at the time of use. In one experiment
124 virus was inactivated by heat treatment at 85°C for 5 min. The ERK MAPK inhibitor
125 U0126 was obtained from Promega Corporation (Madison, WI) and for some

126 experiments U0126 was added to RAW264.7 cells at 40 μ M for 30 min prior to
127 challenge with ATCV-1.

128 **Macrophage challenge with chlorovirus**

129 RAW264.7 cells or thioglycollate induced inflammatory macrophages from C57Bl/6 mice
130 were incubated overnight at 37°C in DMEM at 5×10^5 cells/ml or 1×10^6 cells/ml,
131 respectively. After overnight incubation, non-adherent cells were removed and the
132 adherent cells were exposed to 1 μ l of ATCV-1 containing 10^7 PFU. After 1 h
133 incubation, the non-adsorbed ATCV-1 was aspirated off and 1 ml of fresh DMEM was
134 added. Culture supernatants and cellular lysates for RNA and protein analyses were
135 obtained from samples at 0.5 to 72 h after challenge with ATCV-1. Nitric oxide in
136 culture supernatants from ATCV-1-challenged macrophages was quantified using a
137 Greiss reagent kit from Invitrogen. To evaluate the state of virus-mediated programmed
138 cell death, ATCV-1-challenged macrophages were stained with AlexaFluor647 Annexin
139 V (Invitrogen) plus propidium iodide, then fluorescence-activated cell scanning (FACS)
140 analyzed using a Becton Dickinson FACSCalibur; the data were analyzed using FlowJo
141 software (Treestar, Ashland, OR). To evaluate intracellular ATCV-1, ATCV-1 was
142 incubated with Sytox-orange (Invitrogen), washed with PBS, and then suspended in
143 PBS at 10^{10} PFU/ml. RAW264.7 cells in culture were challenged with 10^7 stained-
144 ATCV-1 for 1 h, after which excess stained ATCV-1 was removed and the adherent
145 RAW264.7 cells incubated for 24 h at 37 °C. Following the incubation, the medium was
146 removed, the cells were washed in PBS, and fixed in 4% paraformaldehyde/PBS and
147 stained with CellMask™ plasma membrane stain immediately prior to confocal

148 microscopy. Localization of stained ATCV-1 was analyzed by the Kalman protocol for
149 confocal microscopy

150

151 **Enumeration of ATCV-1 PFUs**

152 Culture supernatant fractions from macrophages challenged with ATCV-1 were
153 removed and set aside after 1, 24, 48, and 72 h, and macrophages were lysed with 1%
154 Triton X-100 in PBS. The culture supernatants and lysates were combined and
155 assessed for PFU using lawns of *C. heliozoae* cells in agarose as previously described
156 (18).

157

158 **RNA preparation and qRT-PCR**

159 RNA was extracted from ATCV-1-challenged macrophage cells using the Purelink total
160 RNA kit from Ambion/Invitrogen (Carlsbad, CA), according to the manufacturer's
161 specifications. One hundred ng to one μ g of RNA was reverse transcribed in 0.5 mM
162 each of dATP, dGTP, dTTP, and dCTP, 20 U of RNase inhibitor with EasyScript
163 reverse transcriptase (Lambda Biotech) at 42 °C for 50 min followed by 85 °C for 5 min.
164 The cDNA was diluted 1:2 and one μ l was incubated with 0.4 μ M of the following primer
165 pairs designed for mouse genes (Invitrogen): IFN- β sense 5'
166 ATGAACAACAGGTGGATCCTCC 3' and anti-sense 5' AGGAGCTC CTGACATTT
167 CCGAA3'; IL-6 sense 5' ATGAAGTTC CTCTCT GCAAGAGACT 3' and antisense 5'
168 CACTAGGTTTG CCG AGT AGATCTC 3'; IRF7 sense 5' CCAGCGAG
169 TGCTGTTTGGAGAC 3' and antisense 5' TTCCCTAT TTTCCGTGGCTGGG 3'; iNOS
170 sense 5' CCCTTCCGA AGTTTCTG GCAGCAGC 3' and antisense 5'

171 GGCTGTCAGAGCCTCGTGGCTTTGG 3'; or GAPDH sense 5'-TTGTCAGCAAT
172 GCATCCTGCAC-3' and antisense 5'-ACAGCTTTCC AGAGGG GCCATC-3'. ACTV-1
173 major capsid protein (gene *z280l*) mRNA levels were evaluated by qRT-PCR with the
174 primer pairs: sense 5'ATGGCCGGAGGACTTTTCACAGC 3' and antisense 5'
175 AACGGAACCG TTGATGGTCTGC 3. Quantitative (q) PCRs were run on an ABI Prism
176 7000 thermal cycler at 50 °C for 2 min, 95 °C for 10 min, 45 cycles of 95 °C for 15 s/60
177 °C for 30 s. Cycle thresholds (CT) of sample were normalized to the CT of GAPDH for
178 that sample (CT) and then normalized to the average CT of the control samples (CT),
179 after which data were expressed as relative levels of mRNA using $2^{-\Delta\Delta CT}$.

180

181 **FACS Analysis**

182 RAW 264.7 cells were challenged with ATCV-1 at 20 multiplicity of infection (MOI)
183 based on algal cell cultures and then incubated at 37 °C. After 1 h, non-adsorbed ATCV-
184 1 was removed and fresh cell culture medium was added. After 48 h, cells were
185 harvested and washed in cold PBS, re-suspended in Annexin V binding buffer, counted
186 with a hemacytometer, and adjusted to 1×10^6 /ml, after which 5 μ l of AlexaFluor647-
187 conjugated Annexin V (Invitrogen) was added, followed by 0.4 μ g/ml propidium iodide.
188 All samples were analyzed using a Becton Dickinson FACSCalibur and the data were
189 analyzed using FlowJo software.

190

191 **PAGE and western blot analysis**

192 Cell protein lysates were obtained from RAW264.7 cells challenged with ATCV-1 at 30
193 min for up to 72 h. Twenty μ l of each lysate, in sample buffer with bromophenol blue,

194 were electrophoresed on a 10% SDS–Tris-glycine-polyacrylamide gel (SDS-PAGE) and
195 transferred to a nitrocellulose membrane. The membrane was treated with LI-COR
196 (Lincoln, NE) blocking buffer containing fish gelatin for 1 h at room temperature,
197 followed by incubation in a 1:700 dilution of rabbit anti-ATCV-1 IgG, a 1:1000 dilution of
198 mouse anti-phospho-ERK (Cell Signaling, Beverly, MA), a 1:1000 dilution of rabbit anti-
199 ERK (Cell Signaling), a 1:1000 dilution of rabbit anti-cleaved-caspase 3 (Cell Signaling)
200 or 2 µg/ml mouse anti-tubulin antibodies (Invitrogen). These primary antibodies were
201 revealed with either a 1:5000 dilution of IRDye 800CW goat anti-rabbit IgG (Rockland
202 Immunochemicals, Inc., Gilbertsville, PA) or Alexa Fluor 680-labeled anti-mouse IgG
203 (Rockland). The washed membrane was scanned with a LI-COR Odyssey (Lincoln, NE)
204 infrared imaging system.

205

206 **IL-6 protein quantification**

207 To quantify IL-6 in culture supernatants of macrophages challenged with ATCV-1,
208 ELISA plates were coated with 1 µg/ml antibodies to mouse IL-6 (MP5-20F3) (BD
209 Biosciences, San Jose, CA); the plates were blocked with PBS/10% FBS. After washes,
210 cell culture supernatants or serial dilutions of recombinant IL-6 were added to the wells.
211 After 2 h, one µg/ml biotinylated antibody to mouse IL-6 (MP5-32C11) was added to
212 each well. After 1 h, streptavidin conjugated to horseradish peroxidase (1:1000) was
213 added for 30 min and then tetramethylbenzidine substrate/hydrogen peroxide solution
214 was added to each well. All ELISA reagents were purchased from BD-Pharmingen (BD
215 Biosciences, San Jose, CA). IL-6 was measured by determining optical densities at 450
216 nm wavelength with reference wavelength 570 nm.

217

218 **Statistical analysis**

219 Where appropriate, data were analyzed by ANOVA and the Student's *t* test to determine
220 the significance of differences between the sample means. P values of less than 0.05
221 were considered to be significant.

222

223 **RESULTS**224 **ATCV-1 was taken up by and persisted within macrophages**

225 Because DNA sequences resembling chlorovirus ATCV-1 were found in human
226 oropharyngeal tissues and ATCV-1 inoculation of mice increased expression of several
227 pro-inflammatory genes within the hippocampus (4), we examined the response of
228 RAW264.7 mouse macrophage and primary inflammatory mouse macrophage cells to
229 challenge with purified ATCV-1. For comparison, we also challenged BHK-21 cells, a
230 hamster kidney fibroblast cell line, with ATCV-1. In addition, we challenged RAW264.7
231 cells with the chloroviruses PBCV-1 (NC64A type) and CVM-1 (Pbi type). The viruses
232 were allowed to adsorb for 1 h onto seeded RAW264.7, primary macrophages, or BHK-
233 21 cells. Following this initial incubation, the medium was aspirated to remove non-
234 absorbed virus, and replaced with 1 ml of cell culture medium. After 24 and 72 h, cells
235 were examined microscopically for cytopathic effects. RAW264.7 cells challenged with
236 ATCV-1 showed notable signs of cell stress at 24 h that included membrane blebbing,
237 nuclear fragmentation, and some cell death (**Fig. 1A**); in contrast, very few cells with
238 cytopathic effects were seen in mock treated cells or in RAW264.6 cells challenged with
239 either PBCV-1 or CVM-1 (data not shown). Inflammatory macrophages did not exhibit

240 significant cell death by 72 h (**Fig. 2A**). However, inflammatory macrophages
241 challenged with ATCV-1 exhibited prominent dendritic cellular projections compared
242 with mock infected cells.

243 In parallel experiments, after non-adsorbed virus was removed at 1 h, ATCV-1
244 and CVM-1 in cells and culture supernatants were quantified for PFUs on algal *C.*
245 *heliozoae* SAG 3.83 cells or *Micractinium conductrix* cells, respectively, starting at 1 h
246 through 72 h post challenge. In four separate experiments with 5 replicates for each
247 time point, on average 8% of the initial inoculum or 0.8×10^6 PFU/culture were cell
248 associated at 1 h (Fig. 1B). By 24 h ATCV-1 PFU increased further to an average of 2.6
249 $\times 10^6$ PFU/culture declining slightly to 1.9×10^6 PFU/culture by 72 h. Comparing the 1 h
250 PFU with the remainder of the time points, significantly higher amounts of ATCV-1 PFU
251 were seen at 24 to 72 h ($n=20$; $F=10.6$; $p=0.00001$) (**Fig. 1B**). Therefore, ATCV-1
252 persisted and appeared to replicate in the RAW264.7 macrophage cell line. In contrast
253 to ATCV-1, an average of 1×10^4 PFU or 0.1% of the initial CVM-1 inoculum was
254 associated with RAW264.7 cells at 1 h (**Fig. 1D**). The level of CVM-1 in RAW264.7 cells
255 declined at 24 h to an average of 5.6×10^3 PFU/culture and declined further to 2.6×10^3
256 PFU/culture by 72 h. Thus ATCV-1 virus persisted and possibly replicated in
257 RAW264.7 cells while CVM-1 virus did not.

258 ATCV-1 that associated with primary mouse inflammatory macrophages (PECs)
259 at 1 h was 2.7×10^5 PFU/culture or 2.7% of the initial inoculum (**Fig. 2B**). The level of
260 ATCV-1 PFU increased at 24 h to 3.9×10^5 and again at 72 h to an average of $5.0 \times$
261 10^5 /culture. There was a significant increase in ATCV-1 PFUs at 72 h compared with
262 48 h ($p=0.00001$). In contrast to macrophages, BHK-21 cells challenged with MOI = 20

263 ATCV-1 PFU exhibited very low number of PFUs that were cell-associated from 1 to 72
264 h post challenge (**Fig. 2D**). On average only 41 to 49 ATCV-1 PFUs were detected in
265 BHK-21 per cell culture from 1- 72 h post challenge. To determine if ATCV-1 RNA was
266 expressed in RAW264.7 and PEC macrophages that were challenged with ATCV-1,
267 total RNA was isolated, and mRNA for the ATCV-1 major capsid protein (gene *z280l*)
268 was measured by qPCR methods. Both RAW264.7 and PEC macrophages expressed
269 ATCV-1 major capsid protein mRNA starting at 24 h through 72 h post challenge (**Fig.**
270 **2C**). On average 40 copies of major capsid protein mRNA at 24 h, 139 copies at 48 h,
271 and 100 copies at 72 h were detected per RAW264.7 cell culture.

272 To determine if ATCV-1 was internalized by RAW264.7 cells and not simply
273 attached to the cell surface, we stained ATCV-1 with Sytox-orange prior to challenge of
274 cells and then evaluated them in the RAW264.7 cells using confocal microscopy at 24
275 h. Sytox-orange-stained ATCV-1 was equally as infectious to *C. heliozoae* SAG 3.83
276 cells as non-stained ATCV-1, indicating the stain had no effect on virus infectivity in
277 algae (Dunigan, unpublished results). No intracellular fluorescence occurred in control
278 RAW264.7 cells, whereas cells challenged with stained ATCV-1 clearly exhibited cell
279 associated punctate fluorescence consistent with virus association (**Fig. 3A**). To further
280 examine the interaction of RAW264.7 cells with ATCV-1 PFU, we challenged
281 RAW264.7 cells with Sytox-orange-stained ATCV-1 and after 24 h stained the cells with
282 CellMask™ plasma membrane stain prior to confocal microscopy and intracellular virus
283 was identified using the Kalman protocol for confocal microscopy. In this case, Sytox-
284 orange stained virus was seen intracellularly within and beyond the blue plasma
285 membrane stain in RAW264.7 cells (**Fig. 3B**).

286

287 **ATCV-1 proteins were produced in RAW264.7 cells**

288 Antiserum to purified ATCV-1 was generated in rabbits following a series of immunizing
289 injections. Using western blots after applying 10^8 ATCV-1 PFU equivalents to PAGE
290 gels, rabbit anti-ATCV-1 serum reacted with at least 23 distinct proteins (data not
291 shown). To determine if ATCV-1 proteins could be detected in RAW264.7 cells
292 following challenge with ATCV-1, protein lysates generated from 16 to 66 h post
293 challenge were evaluated by western blots using the rabbit anti-ATCV-1 serum. A
294 constant level of a 55 kDa protein similar in size to the ATCV-1 major capsid protein
295 was detected in cellular lysates from RAW264.7 cells from 16 to 66 h post challenge,
296 but not in lysates from mock-challenged cells (**Fig. 4A**). In addition, a 17 kDa protein
297 appeared at 16 h and its intensity increased from 48 to 66 h post challenge. No other
298 anti-ATCV-1 IgG-binding proteins were detected. To determine if these two proteins
299 were from phagocytosis of the original ATCV-1 inoculum or generated during viral
300 challenge, RAW264.7 cells were challenged with either infectious or heat-inactivated
301 ATCV-1. Western blot of protein lysates from cells at 24 to 72 h post challenge
302 revealed that nearly equal levels of the 55 kDa protein were detected at 24 h in
303 RAW264.7 cells challenged with either infectious or heat-inactivated ATCV-1 (**Fig. 4B**).
304 However, at 48 and 72 h the intensity of the 55 kDa protein declined in RAW264.7 cells
305 challenged with heat-inactivated ATCV-1. Moreover, the 17 kDa protein, which
306 appeared in cells challenged with infectious ATCV-1, did not appear at any time in
307 RAW264.7 cells following challenge with heat-inactivated ATCV-1. More importantly,
308 the RAW264.7 cells did not exhibit a cytopathic effect (Fig. 4C). Therefore, two ATCV-

309 1 antisera-reacting proteins were detected in RAW264.7 cells challenged with ATCV-1
310 virus and infectious particles were apparently required to sustain expression of these
311 two proteins. It is not known if other ATCV-1 proteins were expressed in RAW264.7
312 cells but were not produced at a detectable level or were not recognized with the rabbit
313 antisera used in this experiment.

314

315 **ATCV-1 activated programmed cell death in RAW264.7 cells**

316 RAW264.7 cells challenged with infectious ATCV-1 exhibited cytopathic effect and/or
317 died by 72 h. Virus-activated apoptosis is a key antiviral mechanism that limits viral
318 replication (19) but could also contribute to viral persistence through macrophage
319 phagocytosis of apoptotic virus-infected cells(20). Cleavage of caspase 3 (21) and
320 binding of Annexin V to phosphatidylserine at the cell membrane (22) are hallmarks of
321 apoptotic cell death. To determine if RAW264.7 cells challenged with ATCV-1 undergo
322 apoptosis, cells were stained with Annexin V at 48 h and cell extracts were analyzed by
323 western blot for cleaved-caspase 3 at 24 h post challenge. RAW264.7 cells challenged
324 with ATCV-1 at a MOI=20 PFU/cell exhibited a significant increase in cleaved-caspase
325 3 at 24 h (**Fig. 5A**) and robust Annexin V staining at 48 h post challenge (**Fig. 5B**).
326 Therefore, RAW264.7 cells challenged with ATCV-1 appear to undergo apoptotic
327 programmed cell death, which may be an antiviral mechanism that limits virus
328 replication.

329

330 **ATCV-1 activation of ERK MAP-kinases may contribute to apoptosis in RAW264.7** 331 **cells**

332 The MAP kinase ERK is involved in apoptotic programmed cell death in response to
333 DNA damaging agents, but also in response to interferon- α (IFN- α) (23). Therefore, we
334 evaluated ATCV-1-challenged RAW264.7 cells for ERK activation using phospho-
335 specific antibodies in western blots. RAW264.7 cells challenged with ATCV-1 formed
336 phospho-ERK as early as 30 min post challenge that was still present at 60 min, but
337 absent at 3 h post challenge (**Fig. 6A**). A specific inhibitor of ERK activation U0126 was
338 used to pretreat RAW264.7 cells during challenge with ATCV-1 to determine if ERK
339 activation was associated with ATCV-1-induced cell death. Treatment of RAW264.7
340 cells with 40 μ M U0126 during ATCV-1 challenge inhibited ERK activation (**Fig. 6B**).
341 Moreover, U0126 prevented ATCV-1-mediated cytopathic effect and death of
342 RAW264.7 cells (**Fig. 6C**). Therefore, ERK MAP kinases appear to be involved in
343 ATCV-1-induced cytopathic effect of RAW264.7 macrophages.

345 **ATCV-1 induced innate antiviral immune responses in macrophages**

346 A hallmark of viral infection of mammalian cells is the rapid induction of IFN- β and
347 interferon-response genes (ISGs), such as IRF7 (24). To determine if RAW264.7 cells
348 and primary inflammatory macrophages underwent antiviral responses, both IFN- β and
349 IRF7 expression was evaluated post ATCV-1 challenge using qRT-PCR. RAW264.7
350 cells and inflammatory macrophages expressed IFN- β at 72 h and IRF7 by 24 h post
351 challenge with ATCV-1 (**Fig. 7 A, B**). RAW264.7 cells challenged with chlorovirus
352 CVM-1 did not respond with any expression of IFN- β or IRF7 mRNA (data not shown).
353 Therefore macrophages challenged with ATCV-1 appear to undergo some aspects of a
354 canonical innate antiviral response (25).

355

356 **ATCV-1 induced responses in macrophages consistent with shift towards**
357 **inflammatory phenotype**

358 In addition to ISGs, macrophages challenged with viruses also express inflammatory
359 cytokines such as IL-6 and inflammatory factors such as NO, both of which have
360 antiviral effects, and are also involved in neurological memory impairments (12).
361 Therefore we evaluated IL-6 inducible nitric oxide synthase (iNOS) and NO production
362 from RAW264.7 cells and inflammatory macrophages after either mock or ATCV-1
363 challenge. While RAW264.7 cells expressed much higher levels of IL-6 mRNA starting
364 at 24 h post challenge (**Fig. 7C**), both cell types produced similar levels of IL-6 protein
365 within 24 h post challenge with ATCV-1 (**Fig. 7 D**). RAW264.7 cells challenged with
366 chlorovirus CVM-1 did not respond with expression of IL-6 mRNA (data not shown).
367 Likewise RAW264.7 cells responding to ATCV-1 expressed iNOS and produced NO
368 within 24 h post ATCV-1 challenge (**Fig. 8A, B**). In contrast, expression of iNOS from
369 primary inflammatory macrophages did not occur until 72 h post challenge with ATCV-1.
370 Nevertheless, macrophages interacting with ATCV-1 expressed inflammatory factors,
371 many of which are linked to memory impairments and mental illnesses (14, 26, 27).

372 The plasticity of macrophage phenotypes have been noted to take place in
373 response to microbial challenge (28, 29) . One of the phenotypes consistent with
374 inflammatory macrophages results in a metabolic change such that glycolysis is
375 enhanced and oxidative phosphorylation is reduced (30). This aerobic glycolysis results
376 in rapid ATP formation with increased production of lactic acid. To determine if
377 RAW264.7 cells and PEC macrophages exhibit an inflammatory macrophage

phenotype following challenge with ATCV-1, we measured lactate in the culture supernatants. Both RAW264.7 cells (**Fig. 8C**) and PEC macrophages (**Fig. 8D**) that were unchallenged produced slight amounts of lactate over time. However, challenge of both RAW264.7 cells and PEC macrophages with ATCV-1 significantly elevated lactate production into the cell culture medium starting at 24 h post challenge with increasing levels at 48 and 72 h relative to mock-challenged cells.

DISCUSSION

The results of the present investigation show that macrophages challenged with the *Chlorovirus* ATCV-1 took up the virus, maintained and possibly replicated infectious units of it, and underwent responses that included apoptosis, morphological changes, and production of inflammatory factors. The data show with both RAW264.7 cells and peritoneal macrophages that ATCV-1 PFUs increased from 24 h to 72 h post challenge. This suggests that a small but significant amount of viral replication possibly took place in macrophages challenged with ATCV-1. Another cell type, BHK-21, which is a fibroblastic cell line that supports replication of several virus types (31, 32), did not maintain ATCV-1 to any extent and did not exhibit any increase in ATCV-1 PFUs over the 72 h culture period. Thus macrophages may be uniquely suited to maintain viruses that might infect them. For example, Mimiviruses were shown to infect macrophages that phagocytized these giant viruses (33). Moreover influenza viruses infected macrophages, either directly or through phagocytosis of apoptotic macrophages that were previously infected by influenza viruses (34). In this case exposure of phosphatidylserine at the outer leaflet of the cell membrane was the basis for Annexin V

401 staining of apoptotic cells and was a key feature of apoptotic cells assuring their
402 phagocytosis by macrophages. Moreover, viral apoptotic mimicry by enveloped viruses
403 through exposure of phosphatidylserine at their envelop is a well-known mechanism for
404 viral persistence (20). We show here that ATCV-1 infected RAW264.7 cell exhibit
405 robust Annexin V staining at 48 h post challenge. Therefore, viral replication
406 notwithstanding, it is likely that phagocytosis of apoptotic macrophages induced by
407 ATCV-1 contributed significantly to the maintenance of ATCV-1 in macrophage
408 populations.

409 In addition to induction of apoptosis in macrophages, the macrophage responses
410 to ATCV-1 are significant because they included production of inflammatory factors by
411 these cells that have been linked to memory impairments, which occur in mice exposed
412 to ATCV-1 (4). One of the inflammatory factors produced in response to ATCV-1 is IL-6
413 and its production was induced quickly after challenge with ATCV-1. The data indicated
414 that most of the accumulation of IL-6 has occurred within 24 h after ATCV-1 challenge.
415 An interesting aspect of our data is the discrepancy between the amount of IL-6
416 produced and the relative level of IL-6 mRNA expression. This is likely due to the fact
417 that IL-6 production was controlled posttranscriptionally whereby IL-6 mRNA was rapidly
418 degraded (35). As a result production of IL-6 and expression of IL-6 mRNA were not
419 always correlated. Nevertheless it is noteworthy that macrophages respond to ATCV-1
420 with robust IL-6 production, an inflammatory cytokine that causes neurological
421 impairments. It is known that during several different types of viral infections
422 macrophages take up virions, migrate to various anatomical locations, including the
423 CNS, and respond to the viruses by producing inflammatory factors (36). The results

424 here indicate that macrophages could be a host cell that retains ATCV-1 without
425 destroying the virus and responds to the virus with the production of inflammatory
426 factors. Increased levels of pro-inflammatory cytokines are associated with cognitive
427 impairments in a number of human disorders including Alzheimer's disease (37),
428 cognitive decline in the elderly (38), stroke (39), and psychiatric disorders (40). However,
429 it remains to be seen if ATCV-1 infects and induces responses in other cell types of the
430 CNS such as neurons and astrocytes. Moreover, it would not be surprising if brain
431 microglial cells, which are of the macrophage lineage, take up and respond to ATCV-1
432 with production of inflammatory mediators.

433 We also show here that macrophages contained a significant number of
434 infectious ATCV-1 PFU for at least 72 h post challenge and two ATCV-1 proteins
435 appeared to be produced within the macrophages to a degree that was detected by
436 western immunoblot. A 55 kDa protein consistent with the size of the major capsid
437 protein and a 17 kDa protein of unknown identity were produced by RAW264.7 cells
438 challenged with ATCV-1. When heat-inactivated ATCV-1 was used to challenge the
439 RAW264.7 cell line, the 55 kDa protein was detected by western blot for the first 24 h
440 post infection; however, the level of this protein declined after 24 h. This result
441 suggested that some of the 55 kDa protein detected with infectious ATCV-1 was
442 probably from phagocytosed virus particles but some of the 55 kDa protein was likely
443 synthesized *de novo*. In contrast, the unknown 17 kDa protein(s) was not detected at
444 any time when RAW264.7 cells were challenged with heat-inactivated ATCV-1. The
445 level of this same protein(s) increased with time after 24 h post challenge with
446 infectious-ATCV-1. These observations suggest that the 17 kDa protein(s) that reacts

447 with ATCV-1 antiserum was synthesized *de novo* in RAW264.7 cells challenged with
448 ATCV-1. It is likely that other immunoreactive ATCV-1 proteins were synthesized but
449 not detected because they were not produced to a sufficient level in RAW264.7 cells.
450 When purified ATCV-1 virus (10^8 viral particles that were heat inactivated and
451 denatured) was electrophoresed on a polyacrylamide gel and rabbit anti-ATCV-1 sera
452 were used in western blots, 23 distinct proteins were detected (data not shown).
453 However, there were only 5×10^4 PFUs in ATCV-1 challenged RAW264.7 cells at 72 h
454 (Fig. 1B). We conclude that the rabbit anti-ATCV-1 sera would not detect most of these
455 protein unless a threshold of viral particle equivalents is reached, ie. 10^6 or 10^7 . Further
456 analyses, beyond the scope of this study, are required to determine the origin of these
457 proteins, i.e., either host or virus.

458 Another feature of the ATCV-1 challenge of macrophages was a shift in
459 metabolism in these cells towards aerobic glycolysis. ATCV-1 induced lactate
460 production from both RAW 264.7 cells and PECs. The increased lactate production is
461 likely due to establishment of a macrophage phenotype consistent with M1
462 macrophages, which are pivotal to host defense but also to inflammation (29, 30, 41).
463 During this shift in metabolism, oxidative phosphorylation in the mitochondria is
464 disrupted and glycolysis is enhanced. Moreover, it is unclear if the shift in metabolism
465 was initiated by ATCV-1 factors or if it was a response to activation of innate antiviral
466 pathways. Several reports indicate that activation of Toll-like receptor (TLR) pathways
467 triggers the shift in macrophage and dendritic cell metabolism towards glycolysis and
468 away from oxidative phosphorylation (30, 42). As a result of this shift pyruvate is
469 preferentially converted to lactate rather than entry into the TCA cycle. Another feature

470 of this shift in metabolism is increased production of NO, which not only impairs
471 mitochondrial activity, but which also has antiviral activity (43). The response of
472 macrophages to ATCV-1 challenge was a robust production of NO. It remains to be
473 seen if the enhanced production of lactate and NO by macrophages plays any role in
474 the learning impairments associated with ATCV-1 challenge in mice (4) or plays any
475 role in anti-viral activity of macrophages. Nitric oxide is a gaseous cell signaling
476 molecule produced by NO synthases and activates an intracellular signaling enzyme
477 guanylate cyclase (44). While NO is needed by the central nervous system, excess NO
478 is associated with CNS impairments (45). Moreover, there is evidence for activation of
479 microglia, which is part of the macrophage cell lineage, and an increase in iNOS
480 expression in both a rat model for schizophrenia (27) and in patients with schizophrenia
481 (46). Numerous studies report elevated NO production occurs in Alzheimer's disease,
482 multiple sclerosis, and Parkinson's disease (47 48). Therefore, because macrophages
483 retained and responded to ATCV-1, in addition to their migratory properties in response
484 to inflammation, it is possible that macrophages encountering ATCV-1 could initiate
485 responses detrimental to memory formation.

486 In addition to inducing a shift in metabolism, RAW264.7 cells challenged with
487 ATCV-1 initiated apoptotic programmed cell death, as evidenced by increased
488 production of cleaved-caspase 3 and Annexin V staining. Our data suggest that rapid
489 activation of ERK MAP kinases may contribute to the activation of apoptotic death.
490 Addition of the ERK MAP kinase inhibitor U0126 prevented cell death of RAW cells in
491 the presence of ATCV-1. Other reports show the involvement of ERK MAP kinase in
492 activation of apoptosis of cells in response to DNA damaging agents (49) and type I

493 interferons (23). The mechanism by which ATCV-1 induces activation of ERK MAP
494 kinases or apoptotic programmed cell death is unknown.

495 In summary, *Chlorovirus* ATCV-1, a SAG virus that infects the alga *C. heliozoae*
496 an endosymbiont of the heliozoon *Acanthocystis turfacea*, induced powerful
497 inflammatory responses from mouse macrophages that included a shift in metabolism
498 towards aerobic glycolysis with production of lactate, NO and IL-6. Moreover, infectious
499 ATCV-1 virions were retained within the macrophages and ATCV-1 proteins were
500 produced by the inoculated mouse macrophage cell line RAW264.7. Moreover, a low
501 level ATCV-1 replication appeared to occur in RAW264.7 cells. Ultimately ATCV-1
502 activated apoptotic programmed cell death in RAW264.7 cells. Therefore, the
503 hypothesis that ATCV-1 could be sustained and replicate within and trigger
504 neuroinflammatory responses using a macrophage cellular host remains valid.
505 However, it remains to be determined if these pro-inflammatory responses induced by
506 ATCV-1 from macrophages play a role in previously described CNS memory
507 impairments associated with ATCV-1 in both humans and mice (4).

508

509

510 **ACKNOWLEDGEMENTS**

511 This work was supported by funding from the University of Nebraska Medical Center
512 Dept. of Oral Biology and College of Dentistry (TMP), University of Nebraska-Lincoln-
513 Agricultural Research Division (DDD), the Stanley Medical Research Institute (JVE,
514 DDD, RY), and the National Institute of Health grant P30RR031151 from the COBRE
515 program of the National Center for Research Resources. The content is solely the

516 responsibility of the authors and does not necessarily represent the official views of the
517 National Center for Research Resources or the National Institutes of Health.
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538

539 REFERENCES

540

541 1. **Van Etten JL, Dunigan DD.** 2012. Chloroviruses: not your everyday plant virus.542 Trends Plant Sci **17**:1-8.543 2. **Bubeck JA, Pfitzner AJ.** 2005. Isolation and characterization of a new type of

544 chlorovirus that infects an endosymbiotic Chlorella strain of the heliozoon

545 Acanthocystis turfacea. J Gen Virol **86**:2871-2877.546 3. **Fitzgerald LA, Graves MV, Li X, Hartigan J, Pfitzner AJ, Hoffart E, Van Etten**547 **JL.** 2007. Sequence and annotation of the 288-kb ATCV-1 virus that infects an

548 endosymbiotic chlorella strain of the heliozoon Acanthocystis turfacea. Virology

549 **362**:350-361.550 4. **Yolken RH, Jones-Brando L, Dunigan DD, Kannan G, Dickerson F,**551 **Severance E, Sabuncuyan S, Talbot CC, Jr., Prandovszky E, Gurnon JR,**552 **Agarkova IV, Leister F, Gressitt KL, Chen O, Deuber B, Ma F, Pletnikov MV,**553 **Van Etten JL.** 2014. Chlorovirus ATCV-1 is part of the human oropharyngeal

554 virome and is associated with changes in cognitive functions in humans and

555 mice. Proc Natl Acad Sci U S A **111**:16106-16111.556 5. **Redish AD, Touretzky DS.** 1998. The role of the hippocampus in solving the557 Morris water maze. Neural Comput **10**:73-111.558 6. **Howe CL, Lafrance-Corey RG, Sundsbak RS, Lafrance SJ.** 2012.

559 Inflammatory monocytes damage the hippocampus during acute picornavirus

560 infection of the brain. J Neuroinflammation **9**:50.561 7. **Buenz EJ, Rodriguez M, Howe CL.** 2006. Disrupted spatial memory is a562 consequence of picornavirus infection. Neurobiol Dis **24**:266-273.

- 563 8. **Poluektova L, Meyer V, Walters L, Paez X, Gendelman HE.** 2005.
564 Macrophage-induced inflammation affects hippocampal plasticity and neuronal
565 development in a murine model of HIV-1 encephalitis. *Glia* **52**:344-353.
- 566 9. **Moore TC, Cody L, Kumm PM, Brown DM, Petro TM.** 2013. IRF3 helps control
567 acute TMEV infection through IL-6 expression but contributes to acute
568 hippocampus damage following TMEV infection. *Virus Res* **178**:226-233.
- 569 10. **Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N,**
570 **McLoughlin DM, Meaney J, O'Keane V, Connor TJ.** 2012. Reduced
571 expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels
572 are associated with reduced hippocampal volumes in major depressive disorder.
573 *Transl Psychiatry* **2**:e88.
- 574 11. **Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH.** 1997. Progressive
575 decline in avoidance learning paralleled by inflammatory neurodegeneration in
576 transgenic mice expressing interleukin 6 in the brain. *Proc Natl Acad Sci U S A*
577 **94**:1500-1505.
- 578 12. **Sparkman NL, Buchanan JB, Heyen JRR, Chen J, Beverly JL, Johnson RW.**
579 2006. Interleukin-6 Facilitates Lipopolysaccharide-Induced Disruption in Working
580 Memory and Expression of Other Proinflammatory Cytokines in Hippocampal
581 Neuronal Cell Layers. *J Neurosci* **26**:10709-10716.
- 582 13. **Samuelsson AM, Jennische E, Hansson HA, Holmang A.** 2006. Prenatal
583 exposure to interleukin-6 results in inflammatory neurodegeneration in
584 hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning.
585 *Am J Physiol Regul Integr Comp Physiol* **290**:R1345-1356.

- 586 14. **Kamat PK, Tota S, Rai S, Swarnkar S, Shukla R, Nath C.** 2012. A study on
587 neuroinflammatory marker in brain areas of okadaic acid (ICV) induced memory
588 impaired rats. *Life Sci* **90**:713-720.
- 589 15. **Turchyn LR, Baginski TJ, Renkiewicz RR, Lesch CA, Mobley JL.** 2007.
590 Phenotypic and functional analysis of murine resident and induced peritoneal
591 macrophages. *Comp Med* **57**:574-580.
- 592 16. **Petro TM.** 2005. Disparate expression of IL-12 by SJL/J and B10.S
593 macrophages during Theiler's virus infection is associated with activity of TLR7
594 and mitogen-activated protein kinases. *Microbes Infect* **7**:224-232.
- 595 17. **Agarkova IV, Dunigan DD, Van Etten JL.** 2006. Virion-associated restriction
596 endonucleases of chloroviruses. *J Virol* **80**:8114-8123.
- 597 18. **van Etten JL, Burbank DE, Kuczmarski D, Meints RH.** 1983. Virus infection of
598 culturable chlorella-like algae and development of a plaque assay. *Science*
599 **219**:994-996.
- 600 19. **Chattopadhyay S, Fensterl V, Zhang Y, Velepparambil M, Yamashita M, Sen**
601 **GC.** 2013. Role of IRF-3-mediated apoptosis in the establishment and
602 maintenance of persistent infection by Sendai virus. *J Virol* **87**:16-24.
- 603 20. **Amara A, Mercer J.** 2015. Viral apoptotic mimicry. *Nat Rev Microbiol.* 13: 461-
604 469.
- 605 21. **Nicholson DW, Thornberry NA.** 1997. Caspases: killer proteases. *Trends in*
606 *Biochemical Sciences* **22**:299-306.

- 607 22. **Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van**
608 **Oers MH.** 1994. Annexin V for flow cytometric detection of phosphatidylserine
609 expression on B cells undergoing apoptosis. *Blood* **84**:1415-1420.
- 610 23. **Panaretakis T, Hjortsberg L, Tamm KP, Bjorklund AC, Joseph B, Grandeur D.**
611 2008. Interferon alpha induces nucleus-independent apoptosis by activating
612 extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase
613 downstream of phosphatidylinositol 3-kinase and mammalian target of
614 rapamycin. *Mol Biol Cell* **19**:41-50.
- 615 24. **Marie I, Durbin JE, Levy DE.** 1998. Differential viral induction of distinct
616 interferon-alpha genes by positive feedback through interferon regulatory factor-
617 7. *Embo J* **17**:6660-6669.
- 618 25. **Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J.** 2003.
619 Triggering the interferon antiviral response through an IKK-related pathway.
620 *Science* **300**:1148-1151.
- 621 26. **Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A.**
622 2007. Proinflammatory mediators released by activated microglia induces
623 neuronal death in Japanese encephalitis. *Glia* **55**:483-496.
- 624 27. **Ribeiro BM, do Carmo MR, Freire RS, Rocha NF, Borella VC, de Menezes**
625 **AT, Monte AS, Gomes PX, de Sousa FC, Vale ML, de Lucena DF, Gama CS,**
626 **Macedo D.** 2013. Evidences for a progressive microglial activation and increase
627 in iNOS expression in rats submitted to a neurodevelopmental model of
628 schizophrenia: reversal by clozapine. *Schizophr Res* **151**:12-19.

- 629 28. **Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y,**
630 **Loginicheva E, Chmielewski K, Stewart KM, Ashall J, Everts B, Pearce EJ,**
631 **Driggers EM, Artyomov MN.** 2015. Network integration of parallel metabolic
632 and transcriptional data reveals metabolic modules that regulate macrophage
633 polarization. *Immunity* **42**:419-430.
- 634 29. **Pearce EJ, Everts B.** 2015. Dendritic cell metabolism. *Nat Rev Immunol* **15**:18-
635 29.
- 636 30. **Everts B, Amiel E, Huang SC-C, Smith AM, Chang C-H, Lam WY, Redmann**
637 **V, Freitas TC, Blagih J, van der Windt GJW, Artyomov MN, Jones RG,**
638 **Pearce EL, Pearce EJ.** 2014. TLR-driven early glycolytic reprogramming via the
639 kinases TBK1-IKK[epsilon] supports the anabolic demands of dendritic cell
640 activation. *Nat Immunol* **15**:323-332.
- 641 31. **Rubio N, De Felipe C, Torres C.** 1990. Theiler's murine encephalomyelitis virus-
642 binding activity on neural and non-neural cell lines and tissues. *J Gen Virol* **71** (
643 **Pt 12**):2867-2872.
- 644 32. **Ross LJ, Watson DH, Wildy P.** 1968. Development and localization of virus-
645 specific antigens during the multiplication of herpes simplex virus in BHK 21
646 cells. *J Gen Virol* **2**:115-122.
- 647 33. **Ghigo E, Kartenbeck J, Lien P, Pelkmans L, Capo C, Mege JL, Raoult D.**
648 2008. Ameobal pathogen mimivirus infects macrophages through phagocytosis.
649 *PLoS Pathog* **4**:e1000087.

- 650 34. **Fujimoto I, Pan J, Takizawa T, Nakanishi Y.** 2000. Virus clearance through
651 apoptosis-dependent phagocytosis of influenza A virus-infected cells by
652 macrophages. *J Virol* **74**:3399-3403.
- 653 35. **Dhamija S, Kuehne N, Winzen R, Doerrie A, Dittrich-Breiholz O, Thakur BK,**
654 **Kracht M, Holtmann H.** 2011. Interleukin-1 activates synthesis of interleukin-6
655 by interfering with a KH-type splicing regulatory protein (KSRP)-dependent
656 translational silencing mechanism. *J Biol Chem* **286**:33279-33288.
- 657 36. **McKeever PE, Balentine JD.** 1978. Macrophages migration through the brain
658 parenchyma to the perivascular space following particle ingestion. *Am J Pathol*
659 **93**:153-164.
- 660 37. **Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A.** 2014.
661 Accelerated microglial pathology is associated with Abeta plaques in mouse
662 models of Alzheimer's disease. *Aging Cell* **13**:584-595.
- 663 38. **Elderkin-Thompson V, Irwin MR, Hellemann G, Kumar A.** 2012. Interleukin-6
664 and memory functions of encoding and recall in healthy and depressed elderly
665 adults. *Am J Geriatr Psychiatry* **20**:753-763.
- 666 39. **Ormstad H, Verkerk R, Aass HC, Amthor KF, Sandvik L.** 2013. Inflammation-
667 induced catabolism of tryptophan and tyrosine in acute ischemic stroke. *J Mol*
668 *Neurosci* **51**:893-902.
- 669 40. **Barbosa IG, Bauer ME, Machado-Vieira R, Teixeira AL.** 2014. Cytokines in
670 bipolar disorder: paving the way for neuroprogression. *Neural Plast*
671 **2014**:360481.

- 672 41. **Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF,**
673 **Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong**
674 **Z, Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S,**
675 **Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL,**
676 **Gottlieb E, Kelly VP, Clish C, Auron PE, Xavier RJ, O'Neill LAJ.** 2013.
677 Succinate is an inflammatory signal that induces IL-1[bgr] through HIF-1[agr].
678 *Nature* **496**:238-242.
- 679 42. **Tannahill GM, O'Neill LA.** 2011. The emerging role of metabolic regulation in
680 the functioning of Toll-like receptors and the NOD-like receptor Nlrp3. *FEBS Lett*
681 **585**:1568-1572.
- 682 43. **Mehta DR, Ashkar AA, Mossman KL.** 2012. The nitric oxide pathway provides
683 innate antiviral protection in conjunction with the type I interferon pathway in
684 fibroblasts. *PLoS One* **7**:e31688.
- 685 44. **Knowles RG, Palacios M, Palmer RM, Moncada S.** 1989. Formation of nitric
686 oxide from L-arginine in the central nervous system: a transduction mechanism
687 for stimulation of the soluble guanylate cyclase. *Proc Natl Acad Sci U S A*
688 **86**:5159-5162.
- 689 45. **Paakkari I, Lindsberg P.** 1995. Nitric oxide in the central nervous system. *Ann*
690 *Med* **27**:369-377.
- 691 46. **Yao JK, Leonard S, Reddy RD.** 2004. Increased nitric oxide radicals in
692 postmortem brain from patients with schizophrenia. *Schizophr Bull* **30**:923-934.

- 693 47. **Dasgupta S, Jana M, Liu X, Pahan K.** 2002. Myelin basic protein-primed T cells
694 induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis.
695 J Biol Chem **277**:39327-39333.
- 696 48. **Roy A, Ghosh A, Jana A, Liu X, Brahmachari S, Gendelman HE, Pahan K.**
697 2012. Sodium phenylbutyrate controls neuroinflammatory and antioxidant
698 activities and protects dopaminergic neurons in mouse models of Parkinson's
699 disease. PLoS One **7**:e38113.
- 700 49. **Sheridan C, Brumatti G, Elgandy M, Brunet M, Martin SJ.** 2010. An ERK-
701 dependent pathway to Noxa expression regulates apoptosis by platinum-based
702 chemotherapeutic drugs. Oncogene **29**:6428-6441.
- 703
704
705
706
707
708
709
710
711
712
713
714
715
716

717

718 **FIG. 1.** Chlorovirus ATCV-1 was taken up by and persisted within the RAW 264.7
719 macrophage cell line. 5×10^5 RAW264.7 cells grown in culture medium overnight were
720 challenged with 1×10^7 ATCV-1 PFU for 1 h, after which the culture medium containing
721 non-adsorbed ATCV-1 PFUs was removed and fresh culture medium was added to the
722 cells. **(A)** After 24 and 72 h, microscopic differential interference contrast (DIC) images
723 of RAW264.7 cell cultures were taken at 400x magnification; vertical panels represent 3
724 regions of the cell culture field. **(B)** After 1, 24, 48, and 72 h PFUs in cell extracts plus
725 culture supernatants were assessed by viral plaque assays using *C. heliozoae* cell
726 cultures, data were from 4 separate experiments with 5 replicates/time point for each
727 experiment, $n=20$; **(C)** PFUs in cell extracts plus culture supernatants from CVM-1
728 inoculated cells were assessed by viral plaque assays using *Micractinium conductrix*
729 cell cultures, $n=5$ /time point. Values are means \pm standard error..

730

731 **FIG. 2.** Chlorovirus ATCV-1 was taken up and persisted within inflammatory peritoneal
732 exudate macrophage cells (PECs) but not BHK-21 cells. 5×10^5 RAW264.7 cells, 1×10^6
733 PEC cells, and 1×10^6 BHK-21 cells grown in culture medium overnight were
734 challenged with 1×10^7 ATCV-1 PFU for 1 h, after which the culture medium containing
735 non-adsorbed ATCV-1 PFU was removed, and fresh culture medium was added. **(A)**
736 After 24 and 72 h, microscopic DIC images of PEC cell cultures were taken at 400x.
737 Vertical panels represent 3 regions of the cell culture field. **(B)** After 1, 24, 48, and 72 h,
738 PFUs in PEC extracts plus culture supernatants were assessed by viral plaque assays
739 using *C. heliozoae* cell cultures. **(C)** After 24, 48, and 72 h RNA was extracted for qRT-

740 PCR of ATCV-1 major capsid protein (gene *z280l*) mRNA expression. **(D)** After 1, 24,
741 48, and 72 h, PFUs in BHK-21 extracts plus culture supernatants were assessed by
742 viral plaque assays. Values are means \pm standard error, $n=5$. * indicates significantly
743 different than values at 48 h.

744

745 **FIG. 3.** ATCV-1 virions appeared to be intracellular in RAW264.7 cells 24 h post
746 challenge. Purified ATCV-1 was incubated with Sytox Orange for 1 h, after which
747 virions were washed twice in PBS and used to challenge RAW cells. 5×10^5 RAW cells
748 grown in culture medium overnight were challenged with 1×10^7 stained ATCV-1 PFU for
749 1 h, after which the culture medium and non-adsorbed ATCV-1 PFU were removed, and
750 fresh culture medium was added. After 24 h RAW264.7 cells were (A) imaged with
751 fluorescence microscopy or (B) washed once in cell culture media, fixed in 4%
752 paraformaldehyde, and membrane stained with CellMask™ plasma membrane stain.
753 Panel **A** represents cells imaged with DIC and fluorescence; panel **B** represents cells
754 imaged by confocal microscopy with intracellular ATCV-1 identified using the Klamann
755 protocol for confocal microscopy.

756

757 **FIG. 4.** Chlorovirus ATCV-1 proteins were expressed within RAW 264.7 cells
758 challenged with infectious ATCV-1. 5×10^5 RAW cells grown in culture medium
759 overnight were challenged with 1×10^7 infectious ATCV-1 PFU or heat-inactivated ATCV-
760 1 for 1 h, after which culture medium and non-adsorbed ATCV-1 PFU were removed,
761 and fresh culture medium was added. **(A)** Immunoblot of cell lysates 16, 24, 48, and 66
762 h after challenge with infectious ATCV-1 using rabbit anti-ATCV-1 serum; **(B)**

763 immunoblot of cell lysates 24, 48, and 72 h after challenge with infectious or heat-
764 inactivated ATCV-1(85°C for 5 min); **(C)** after 72 h following challenge with infectious or
765 heat-inactivated ATCV-1, microscopic images of RAW264.7 cell cultures were taken at
766 400x magnification.

767

768 **FIG. 5.** Chlorovirus ATCV-1 induced apoptotic programmed cell death in RAW 264.7
769 cells. 5×10^5 RAW26.7 cells grown in culture medium overnight were challenged with
770 1×10^7 ATCV-1 PFU, after which culture medium and non-adsorbed ATCV-1 PFU were
771 removed, and fresh culture medium was added. **(A)** Immunoblot of cell lysates from
772 one unchallenged RAW264.7 cell culture and three ATCV-1 challenged RAW264.7 cell
773 cultures at 24 h using rabbit anti-cleaved-caspase3 and mouse anti-beta tubulin
774 antibodies; **(B)** FACS analysis of propidium iodide and Annexin V staining at 48 h post
775 challenge with ATCV-1.

776

777 **FIG. 6.** ERK MAP kinases were activated in RAW 264.7 cells challenged with infectious
778 ATCV-1. **(A)** 5×10^5 RAW264.7 cells grown in culture medium overnight were
779 challenged with 1×10^7 ATCV-1 PFUs. Immunoblot of RAW264.7 cell lysates 30, 60,
780 180, and 360 min after challenge with infectious ATCV-1 using mouse anti-phospho
781 ERK1/2 and rabbit anti-ERK1/2 antibodies; **(B, C)** 5×10^5 RAW cells grown in culture
782 medium overnight were treated with 40 μ M U0126 for 30 min prior to challenge with
783 1×10^7 infectious ATCV-1. **(B)** Phospho-ERK immunoblot of RAW 264.7 cell lysates at
784 30, 60, and 120 min and 48 h; **(C)** microscopic images of RAW264.7 cell cultures taken

785 at 400x magnification after 72h. Vertical panels represent 3 regions of the cell culture
786 field.

787

788 **FIG. 7.** Chlorovirus ATCV-1 challenged RAW 264.7 cells and peritoneal exudate cell
789 (PEC) macrophages expressed an antiviral response with inflammatory cytokine IL-6.
790 5×10^5 RAW cells or 1×10^6 PEC macrophages grown in culture medium overnight were
791 challenged with 1×10^7 ATCV-1 PFU for 1 h, after which culture medium and non-
792 adsorbed ATCV-1 PFU were removed, and fresh culture medium was added. After 24,
793 48, and 72 h RNA was extracted from cellular lysates and for qRT-PCR of **(A)** IFN- β ;
794 **(B)** IRF7; **(C)** IL-6 and culture supernatants were collected for ELISA of **(D)** IL-6 protein.
795 Values are means \pm standard error, n=5.




796

797 **FIG. 8.** Chlorovirus ATCV-1 challenged RAW 264.7 cells and peritoneal exudate cell
798 (PEC) macrophages expressed iNOS, nitric oxide and secreted elevated levels of
799 lactate. 5×10^5 RAW cells or 1×10^6 PEC macrophages grown in culture medium
800 overnight were challenged with 1×10^7 ATCV-1 PFU for 1 h, after which culture medium
801 and non-adsorbed ATCV-1 PFU were removed, and fresh culture medium was added.
802 After 24, 48, and 72 h RNA was extracted from cellular lysates and culture supernatants
803 collected for **(A)** Greiss assay of nitric oxide; **(B)** qRT-PCR of iNOS; **(C, D)** secreted
804 lactate assay. Values are means \pm standard error, n=5.


805

806


807

A**B****C**


A




B







C







D







A**B****C**









A



B



C



D

